<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431093</url>
  </required_header>
  <id_info>
    <org_study_id>P06673</org_study_id>
    <secondary_id>C-1755</secondary_id>
    <nct_id>NCT00431093</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)</brief_title>
  <acronym>TOTAL</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Double Dummy, Group-Comparative Trial to Compare the Effects of Livial® and Activelle ® on the Vaginal Bleeding Pattern, Vasomotor Complaints, Vaginal Atrophy, QoL and Sexual Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial is undertaken to compare the effects of Tibolone with a low-dose HRT&#xD;
      regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For the bleeding evaluation, subject will be given a diary card to record the days on which no bleeding, vaginal spotting or bleeding occurs</measure>
    <time_frame>starting from baseline and during the whole trial period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hot flushes recorded on a daily diary card during the whole trial period.</measure>
    <time_frame>Entire trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A mammography to assess breast density and blood samples to determine the changes in endocrine parameters.</measure>
    <time_frame>screening and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A vaginal smear to assess the Vaginal Maturation Index and the Karyopycnotic Index results</measure>
    <time_frame>Baseline and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urogenital complaints assessed with the Local Urogenital Complaints Rating Scale.</measure>
    <time_frame>At baseline, week 12, week 24 and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life measured with the Women's Health Questionnaire 36-items (WHQ-36) the McCoy Female Sexuality Questionnaire-Short Form 9-items (MFSQ-SF) collecting prospectively medical resources utilization items</measure>
    <time_frame>At baseline and week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">570</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tibolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low-dose estradiol/noresterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tibolone</intervention_name>
    <description>uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Livial</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose estradiol/noresterone</intervention_name>
    <description>Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.&#xD;
Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Activelle®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be healthy and postmenopausal women, &gt;= 45 and &lt; 65 years of age, with&#xD;
             an intact uterus.&#xD;
&#xD;
          -  Subjects must have been postmenopausal for less than 15 years.&#xD;
&#xD;
          -  Body Mass Index &gt;18 and =&lt; 32 kg/m2.&#xD;
&#xD;
          -  Voluntary written informed consent is required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unexplained abnormal uterine bleeding after the menopause.&#xD;
&#xD;
          -  Double layer endometrial thickness = 6 mm as assessed by transvaginal ultrasonography.&#xD;
&#xD;
          -  Treatment with oral estrogen and/or progestogen therapy within 4 weeks prior to&#xD;
             screening, or treatment with transdermal therapy and local estrogen applications&#xD;
             within 4 weeks prior to screening.&#xD;
&#xD;
          -  Any previous or current unopposed estrogen administration, prior use of estrogen&#xD;
             pellets or tamoxifen citrate (occasional use of estrogen-containing vaginal cream is&#xD;
             allowed after the appropriate wash-out period is completed). Estrogen combined with&#xD;
             sequential administration of progestogen should have been at least 10 days per 28 day&#xD;
             cycle.&#xD;
&#xD;
          -  The following wash-out periods apply:&#xD;
&#xD;
               -  4 weeks for transdermal hormonal treatment, local estrogen applications or other&#xD;
                  non-hormonal medication known to act on the relief of vasomotor symptoms (e.g.&#xD;
                  clonidine)&#xD;
&#xD;
               -  4 weeks for phytoestrogens, tibolone, intra-uterine or oral progestogen and oral&#xD;
                  estrogen/progestogen therapy&#xD;
&#xD;
               -  6 months for progestogen implants or injections and estrogen/progestogen&#xD;
                  injectable therapy.&#xD;
&#xD;
          -  Any subjects who are either using phytoestrogens, tibolone, intra-uterine or oral&#xD;
             progestogen, progestogen implants or injections, estrogen/progestogen combination&#xD;
             therapy or any other non-hormonal medication known to act on the relief of vasomotor&#xD;
             symptoms and who have not observed the appropriate wash-out periods (see previous&#xD;
             exclusion criteria).&#xD;
&#xD;
          -  Any serious disease or disorder; or any endocrine disorder; (controlled&#xD;
             hypo/hyperthyroidism and diabetes mellitus Type II is allowed).&#xD;
&#xD;
          -  Diseases for which exogenous hormonal steroids are contraindicated.&#xD;
&#xD;
          -  History or presence of any malignancy, except successfully treated nonmelanoma skin&#xD;
             cancers.&#xD;
&#xD;
          -  History or presence of cardiovascular or cerebrovascular conditions:&#xD;
&#xD;
               -  thrombophlebitis, thrombosis or thromboembolic disorders.&#xD;
&#xD;
          -  History or presence of liver, gallbladder (subjects who have had a cholecystectomy&#xD;
             will not be excluded) or renal disease, epilepsy or classical migraine headaches.&#xD;
&#xD;
          -  History or presence of clinically significant depression or other psychiatric&#xD;
             disorders which, in the investigator's judgment, might compromise or confound the&#xD;
             subject's participation in the trial.&#xD;
&#xD;
          -  Uncontrolled high blood pressure: systolic pressure &gt; 170 mmHg and/or diastolic&#xD;
             pressure &gt; 105 mmHg, measured after 5 minutes in a sitting position.&#xD;
&#xD;
          -  Abnormal cervical Pap smear (corresponding to PAP = III, or LSIL, HSIL, ASCUS, AGCUS&#xD;
             in the Bethesda classification)&#xD;
&#xD;
          -  Abnormal, clinically significant results of the mammography.&#xD;
&#xD;
          -  Presence of fibrocystic disease of the breast.&#xD;
&#xD;
          -  Presence of otosclerosis.&#xD;
&#xD;
          -  Known hypersensitivity to any of the ingredients of the trial medication.&#xD;
&#xD;
          -  Any subjects using either steroids, drugs known to affect sexual functioning and mood&#xD;
             (antidepressants, psychoactive drugs, sedatives, neuroleptics, narcotics,&#xD;
             benzodiazepines), drugs know to interfere with the pharmacokinetics of the steroids&#xD;
             (hydantoins, primidone, rifampicin, barbiturates, carbamazepine, griseofulvin,&#xD;
             warfarin, ketoconazole, or products containing St. John's wort), or raloxifene&#xD;
             hydrochloride. A wash-out period of 4 weeks will apply to subjects using these drugs.&#xD;
             Sporadical use of benzodiazepines (twice or less a week) is allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 2, 2007</study_first_submitted>
  <study_first_submitted_qc>February 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2007</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tibolone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

